Kazakhstan Medical Device Registration Prerequisites: Dual Pathways and Transition Deadlines

1. Key takeaways

Kazakhstan applies a registration-first regime for medical devices: no device may be manufactured, imported, placed on the market or used in the country until it has completed national registration and been entered in the national register. The register entry itself is the legal carrier of the right to circulate the device. Documents issued by foreign authorities do not create a lawful basis for market access in Kazakhstan. A CE certificate issued under the European regulatory system, an FDA clearance in the United States, or an NMPA registration certificate in China may support the technical dossier, but none of them replaces Kazakh registration. Two compliance entry points exist today. The first is national registration under Kazakh rules, which results in a national registration certificate, referred to in practice as the RU certificate. The second is registration under the common rules of the Eurasian Economic Union, which results in a Union registration certificate. Under the protocol amending the 2014 Agreement, the window for submitting new applications under national member-state rules closes on December 31, 2027, while variations and dossier alignment for existing certificates may continue until December 31, 2028. The practical consequence is that every month of delay narrows the national pathway, so the choice between the two pathways should be made at project initiation rather than after dossier preparation has already started.

2. Legal basis

3. Expert insights

Insight one: registration-first is not notification-first. Kazakhstan requires that a device be entered in the national register before any lawful circulation arises; the register entry itself carries the legal right to market the product. This differs materially from markets that rely on notification, listing or declaration schemes. GRZAN treats consistency between the register entry and the physical product as the first-round checkpoint in every project, rather than deferring the comparison to customs clearance, when discrepancies are far more expensive to correct. A mismatch discovered at the border can lead to detention of goods, re-submission of dossier elements and suspension of supply, while the same mismatch identified at project start costs only a documentation revision.

Insight two: registration covers units, not product names. Whether a shipment is covered by a registration depends on four elements: the manufacturer, the manufacturing site, the model (including its configuration) and the intended use. If any single element differs, the goods are treated as an unregistered device, regardless of commercial naming or catalogue descriptions. This practical estimate corresponds directly to the granularity at which the national register records information, which is why a family of products sold under one commercial name may still require separate register entries for each configuration actually shipped.

Insight three: two entry points, two deadline layers, and a layered structure more valuable than in most markets. New applications under national rules must be submitted by December 31, 2027; variations and dossier alignment for existing certificates may continue until December 31, 2028. More importantly, medical device registration certificates obtained under national rules carry no expiry date. Each national registration completed before the window closes therefore locks in long-term market access, rather than creating a temporary qualification that must be periodically renewed. Few neighbouring markets offer an equivalent combination of a defined transition window and an open-ended certificate, which is what makes the current period strategically significant for manufacturers planning Central Asian expansion.

4. Practical recommendations

1. Lock down the four elements (manufacturer, manufacturing site, model and configuration, intended use) at project initiation and write them into the specification annex of commercial contracts, so that procurement, regulatory and distribution teams all work from the same reference.
2. Plan national registration projects backwards from December 31, 2027 as a hard deadline: laboratory testing schedules and sample shipping typically consume more calendar time than the review itself, and both must be sequenced before dossier submission.
3. When presenting CE or FDA documents to Kazakh customers or distributors, annotate them with a statement that they do not constitute a basis for circulation in the Republic of Kazakhstan, and never allow them to be used as proof of registration in tenders or customs files.
4. For new products planned to enter after 2028, start preparing the evidence package to the depth required by the Union rules now, since the national pathway will no longer be available by then.

5. Verification checklist

• □ Every model can be located in the Kazakhstan national register or the Union unified register with a corresponding record
• □ The manufacturer and manufacturing site in the register entry match the physical product labelling
• □ If submitting a new application under national rules, submission falls before December 31, 2027
• □ If handling variations and dossier alignment under national rules, submission falls before December 31, 2028
• □ The specification annex of commercial contracts matches the model configuration stated in the registration documents
• □ No CE certificate, FDA clearance, voluntary GOST-K certificate or declaration of conformity has been used as a substitute for proof of registration

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering pathway selection, dossier preparation, expert review follow-up and register maintenance. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.